Is Mangoceuticals Inc. Common Stock a good investment? Mangoceuticals Inc. Common Stock (MGRX) is currently trading at 0.4506 USD.
Earnings Schedule: Mangoceuticals Inc. Common Stock is expected to release its next earnings report on March 19, 2026.
No, it does not currently pay a dividend.
Mangoceuticals Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 19, 2026. The company currently has a trailing EPS of -1.00.
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 16, 2024 | 0.07 |
Community Discussion